Skip to main content
News

Real-World Study Finds Elevated Thromboembolic Risk in Polycythemia Vera

Edited by 

Key Takeaways

  • A US real-world study of 20 089 patients with polycythemia vera (PV) found that 25.1% experienced at least 1 thromboembolic event (TE) during follow-up.
  • TE incidence was highest among patients with prior thrombosis (50.2%), compared with age-based high-risk (25.0%) and low-risk patients (13.3%).
  • Prior TEs, elevated white blood cell counts, and higher hematocrit levels were associated with increased thromboembolic risk, highlighting opportunities for improved disease management.

A retrospective US study published in Clinical Lymphoma, Myeloma & Leukemia found that approximately 1 in 4 patients with PV experienced a TE during follow-up, including patients traditionally classified as low-risk. The findings suggest that conventional risk stratification based on age and prior thrombosis may not fully capture thromboembolic risk.

Study Design and Thromboembolic Event Rates

Researchers analyzed electronic health records and linked insurance claims from Optum's Market Clarity database between 2007 and 2019. The study included 20 089 patients with newly diagnosed or established PV, with a median follow-up of 4.4 years.

Patients were classified into 3 groups: event-based high-risk (prior TE at any age), age-based high-risk (aged 60 years or older without prior TEs), and low-risk (younger than 60 years without prior TEs).

Overall, 5035 patients (25.1%) experienced at least 1 post-index TE. Event rates varied substantially across risk groups:

  • Event-based high-risk: 50.2%
  • Age-based high-risk: 25.0%
  • Low-risk: 13.3%

The most frequently reported arterial events were stroke (7.1%) and myocardial infarction/acute coronary syndrome (6.4%). Common venous events included deep vein thrombosis/deep thrombophlebitis (8.1%) and pulmonary embolism (4.5%).

Multivariate analyses identified prior thrombosis as the strongest predictor of subsequent TEs (hazard ratio [HR], 2.60; 95% CI, 2.38-2.85). White blood cell counts of at least 25 000/μL were also associated with increased risk (HR, 1.89; 95% CI, 1.50-2.39).

Additionally, each 1-percentage-point increase in median post-index hematocrit was associated with approximately 3% greater TE hazard.

Clinical Implications for Polycythemia Vera Management

The findings highlight persistent thromboembolic risk across PV populations, including younger patients without previous thrombosis.

Current PV management strategies emphasize maintaining hematocrit below 45% through therapeutic phlebotomy, low-dose aspirin, and/or cytoreductive medications, depending on individual risk.

However, the occurrence of TEs among low-risk patients suggests that age and thrombotic history alone may be insufficient for comprehensive risk assessment.

For managed care stakeholders, the findings underscore the importance of evaluating treatment effectiveness and disease monitoring across risk categories. The investigators also noted that thromboembolic complications are associated with substantial health care costs and resource utilization.

Researchers Highlight Need for Improved Risk Assessment

The authors emphasized the limitations of conventional risk classification: “Our findings demonstrate that while patients with a prior history of TEs had the highest thromboembolic risk, all patients were at risk of TEs.”

They concluded that thromboembolic risk reduction should remain a priority across all patient groups, with improved understanding of risk markers potentially supporting more individualized management.

Overall, this large US real-world analysis demonstrates that TEs remain a substantial complication of polycythemia vera regardless of baseline risk classification. The findings support continued investigation into risk assessment, hematocrit control, and therapeutic strategies to reduce thrombotic complications.

Reference

Kuykendall AT, Molina A, Reaven N, et al. Risk of thromboembolic events in patients with polycythemia vera: a real-world observational study. Clin Lymphoma Myeloma Leuk. 2026;26(8):549-561. doi:10.1016/j.clml.2026.05.006